- About
- Home
- Introduction
- Statistics
- Programs
- Dignet
- Gene
- GenePair
- Help & Docs
- Documents
- Help
- FAQs
- Links
- Acknowledge
- Disclaimer
- Contact Us
Gene Information
Gene symbol: VIPR1
Gene name: vasoactive intestinal peptide receptor 1
HGNC ID: 12694
Synonyms: VPAC1, RDC1, HVR1, VPAC1R
Related Genes
| # | Gene Symbol | Number of hits |
| 1 | ADCY10 | 1 hits |
| 2 | ADCYAP1 | 1 hits |
| 3 | ADCYAP1R1 | 1 hits |
| 4 | DUSP2 | 1 hits |
| 5 | IL10 | 1 hits |
| 6 | INS | 1 hits |
| 7 | LIF | 1 hits |
| 8 | NTS | 1 hits |
| 9 | VIP | 1 hits |
| 10 | VIPR2 | 1 hits |
Related Sentences
| # | PMID | Sentence |
| 1 | 7912431 | The reported VIP receptor antagonist, neurotensin(6-11)-VIP(7-28), was also an agonist. |
| 2 | 11978642 | Activation of VPAC1 has been implicated in elevating glucose output, whereas activation of VPAC2 may be involved in insulin secretion. |
| 3 | 15994369 | From binding studies of their abilities to directly interact with hVPAC1 (T47D cells, hVPAC1-transfected cells) and hVPAC2 (Sup T1- and VPAC2-transfected cells) and to stimulate adenylate cyclase in each, two analogs [(Ala(2,8,9,11,19,22,24,25,27,28))VIP and (Ala(2,8,9,11,19,24-28))VIP] were found to have >2000- and >600-fold selectivity for hVPAC1. |
| 4 | 17559974 | Both peptides bind to their common G-protein-coupled receptors, VPAC1 and VPAC2, and PACAP, in addition to the specific receptor PAC1, all three of which are expressed in islets. |
| 5 | 19633131 | VIP receptors, Vipr1 and Vipr2 (Vpac1 and Vpac2), were expressed at the implantation sites and VIP induced leukemia inhibitory factor (LIF) and Treg marker expression in both strains; however, a reduced Vip expression was found in NOD implantation sites. |
| 6 | 20800633 | The proliferative response to the glucose-enriched environment was correlated to changes in the expression of PAC1 and, to a minor extent, to VPAC2, but not VPAC1 receptors, as measured by quantitative real-time PCR. |
| 7 | 21129425 | The results of histopathological and immunohistochemical analysis showed that VIP and the VPAC1 agonist improved the structure and cellularity of islets and ameliorated the insulin-secreting activity of islets. |
| 8 | 21129425 | Additionally, administration of VIP or the VPAC1 agonist not only significantly decreased the plasma TNF? and CRP and promoted IL-10 in diabetic mice but also blocked the increased NF-?B activity of pancreatic tissue in diabetic mice. |